Human cytomegalovirus-specific CD4+ and CD8+ T-cell response determination: Comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host

Clinical Immunology

Volumn 136, Issue 2, 2010, Pages 269-281

  Zelini, Paola ^a   Lilleri, Daniele ^a   Comolli, Giuditta ^a   Rognoni, Vanina ^a   Chiesa, Antonella ^a   Fornara, Chiara ^a   Locatelli, Franco ^b   Meloni, Federica ^b   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Epitopic peptide pool; Human cytomegalovirus; Immunocompetent host; Immunocompromised patients; Infected cell lysate; Infected dendritic cells; T cell response

Indexed keywords

ADULT; ARTICLE; CD4 CD8 RATIO; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; RECIPIENT;

ADOLESCENT; ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOASSAY; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; INFANT; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; YOUNG ADULT;

EID: 77954310031     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.04.008     Document Type: Article

References (55)

1. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N. Engl. J. Med. 1998, 338:1741-1751.
2. Boeckh M., Ljungman P. Cytomegalovirus infection after bone marrow transplantation. Transplant Infections 1998, 215-227. Lippincott-Raven, Philadelphia. C. Paya (Ed.).
3. Gerna G., Baldanti F., Torsellini M., et al. Evaluation of human cytomegalovirus DNAemia vs pp 65-antigenemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir. Ther. 2007, 12:63-72.
4. Lilleri D., Gerna G., Furione M., et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem cell transplantation compared with pp65-antigenemia. Blood 2007, 110:2757-2760.
5. Cytomegalovirus. Am. J. Transplant. 2004, 4(S10):51-58.
6. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 1993, 118:173-178.
7. Locatelli F., Percivalle E., Comoli P., et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenemia on patients' outcome. Br. J. Haematol. 1994, 88:64-71.
8. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
9. + T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 2006, 6:2356-2364.
10. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006, 108:1406-1412.
11. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 932:248-256.
12. Quinnan G.V., Kirmani N., Rook A.H., et al. Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 1982, 307:7-13.
13. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
14. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
15. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 2000, 243:147-154.
16. Lilleri D., Fornara C., Furione M., Zavattoni M., Revello M.G., Gerna G. Development of human cytomegalovirus-specific T-cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J. Infect. Dis. 2007, 195:1062-1067.
17. Jerome K.R., Sloan D.D., Aubert M. Measuring T-cell-mediated cytotoxicity using antibody to activated caspase 3. Nat. Med. 2003, 9:4-5.
18. Waldrop S.L., Pitcher C.J., Peterson D.M., Maino V.C., Picker L.J. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 1997, 99:1739-1750.
19. Hebart H., Daginik S., Stevanovic S., et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002, 99:3830-3837.
20. Altman J.D., Moss P.A., Goulder P.J.R., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
21. Kern F., Surel I.P., Brock C., et al. T-cell epitope mapping by flow cytometry. Nat. Med. 1998, 4:975-978.
22. + T cells. Blood 2002, 100:3690-3697.
23. + T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 2000, 30:1676-1682.
24. Maecker H.T., Dunn H.S., Suni M.A., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 2001, 255:27-40.
25. Rodgers B., Borysiewicz L., Mundin J., Graham S., Sissons P. Immunoaffinity purification of a 72K early antigen of human cytomegalovirus: analysis of humoral and cell-mediated immunity to the purified polypeptide. J. Gen. Virol. 1987, 68:2371-2378.
26. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus is dominated by structural protein pp 65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J. Virol. 1996, 70:659-679.
27. +-T-cell responses reactivities in healthy carriers. J. Virol. 2003, 77:7401-7410.
28. Sylwester A.W., Mitchell B.L., Edgar J.B., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
29. Walker S., Fazou C., Crough T., et al. Ex-vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using quantiFERON®-CMV. Transplant. Infect. Dis. 2007, 9:165-170.
30. Kumar D., Chernenko S., Moussa G., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 2009, 9:1214-1222.
31. + T cell recovery. Clin. Immunol. 2007, 124:200-206.
32. + T-cell immunity. Am. J. Transplant. 2008, 8:1749-1754.
33. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur. J. Immunol. 2005, 35:1795-1804.
34. Lilleri D., Zelini P., Fornara C., Comolli G., Gerna G. Inconsistent responses of cytomegalovirus-specific T-cells to pp 65 and IE-1 vs infected dendritic cells in organ transplant recipients. Am. J. Transplant. 2007, 7:1997-2005.
35. + T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin. Immunol. 2009, 131:395-403.
36. Salvaneschi L., Perotti C., Zecca M., et al. Extracorporeal photochemotherapy for treatment of acute and chronic GvHD in childhood. Transfusion 2001, 41:1299-1305.
37. Ljungman P., Griffiths P., Paya C. Definition of HCMV infection and disease in transplant recipients. Clin. Infect. Dis. 2002, 34:1094-1097.
38. Gerna G., Vitulo P., Rovida F., et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J. Med. Virol. 2006, 78:408-416.
39. Erratum. J. Med. Virol. 2008, 80:1869.
40. Gerna G., Lilleri D., Rognoni V., et al. Preemptive therapy of systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am. J. Transplant. 2009, 9:1142-1150.
41. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179:1109-1118.
42. Lilleri D., Gerna G., Fornara C., et al. Human cytomegalovirus-specific T-cell reconstitution in young patients receiving T-cell-depleted, allogeneic hematopoietic stem cell transplantation. J. Infect. Dis. 2009, 199:829-836.
43. + T cells. J. Gen. Virol. 2005, 86:275-284.
44. Pepperl S., Münster J., Mach M., Harris J.R., Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 2000, 74:6132-6146.
45. Bunde T., Kirchner A., Hoffmeister B., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 2005, 201:1031-1036.
46. La Rosa C., Limaye A.P., Krishnan A., Longmate J., Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J. Infect. Dis. 2007, 195:633-644.
47. Gratama J.W., Brooimans R.A., van der Holt B., et al. Monitoring cytomegalovirus IE-1 and pp 65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B 2008, 74B:211-220.
48. + T cells and control of HCMV replication after allogeneic stem cell transplantation. J. Virol. 2008, 82:10143-10152.
49. Kirchner A., Hoffmeister B., Cherepnev-G G., et al. Dissection of the CMV specific T-cell response is required for optimized cardiac transplant monitoring. J. Med. Virol. 2008, 80:1604-1614.
50. Nebbia G., Mattes F.M., Smith C., et al. Polyfunctional cytomegalovirus-specific CD4+ and pp 65 CD8+ T cells protect against high-level replication after liver transplantation. Am. J. Transplant. 2008, 8:2590-2599.
51. + cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J. Infect. Dis. 2005, 191:977-984.
52. Lacey S.F., La Rosa C., Zhou W., et al. Functional comparison of T cells recognizing cytomegalovirus pp 65 and immediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J. Infect. Dis. 2006, 194:1410-1421.
53. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 1999, 73:8179-8184.
54. Gyulai Z., Endresz V., Burian K., et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp 65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis. 2000, 181:1537-1546.
55. Sester U., Gartner B.C., Wilkens H., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant. 2005, 5:1483-1489.